Background and Purpose: Numerous studies have demonstrated an association between acute cardiac events, cerebrovascular accidents, and cocaine use. The underlying mechanisms leading to these complications have not been well defined. Using various in vitro model systems, it has been reported that cocaine, up to or greater than an order of magnitude of the lethal dose, causes either inhibitory or proaggregatory effects on platelet function.
C oincident with the recent dramatic increase in cocaine abuse in the United States, an increasing number of strokes temporally related to cocaine use have been reported.' In most but not all series, the majority of these strokes were hemorrhagic.1-4 Underlying vascular lesions, especially aneurysm and arteriovenous malformation, have been identified in three fourths and one half of the cases of cocaine-related subarachnoid and intracerebral hemorrhages, respectively.3 It is in those cases that lack an identifiable etiology that cocaine may have been directly responsible for the stroke. Further strengthening this association between cocaine and cerebral hemorrhage are cases in which bleeding occurred in multiple and unusual locations.3,5 Postulated mechanisms for cocaine-related cerebral hemorrhage include acute hypertension and profound cerebral vasoconstriction followed by reperfusion.235 These mechanisms, however, remain unproven. Coagulation disorders, especially those related to platelet dysfunction after cocaine use, have, until recently, received little attention.
O'Brien and Boullin6 were the first to report that local anesthetics at various concentrations inhibited platelet adhesion to foreign surfaces and platelet aggregation initiated by ADP and thrombin. Additional studies have demonstrated that exposure of blood platelets to tertiary amine local anesthetics such as dibucaine, procaine, and tetracaine results in the inhibition of platelet activation and aggregation. 6 18 Treatment of blood platelets with dibucaine caused decreased fibrinogen receptor exposure on the activated platelet and decreased calcium uptake and exchange across the platelet membrane. 15 Feinstein et a19 reported that local anesthetics directly inhibited aggregation, and this inhibition was partially antagonized by calcium; the platelet release reaction was also blocked by local anesthetics independent of external calcium concentrations or the aggregation response.
With regard to cocaine, it has been demonstrated that, in addition to human platelet aggregation, rabbit platelet aggregation induced by ADP and thrombin was inhibited by pretreatment with cocaine. 19 On the other hand, it has been shown that cocaine enhances the response of rabbit platelets to arachidonic acid, possibly potentiating thromboxane generation and platelet aggregation. 20 In view of these conflicting reports, a critical analysis of the effect of various concentrations of cocaine on human platelet activation and aggregation is needed. We found that cocaine, up to an order of magnitude greater than predicted systemic concentrations of lethal doses, inhibited human platelet aggregation induced by the agonists ADP, collagen, and arachidonic acid and also caused disaggregation of platelets. Interestingly, at these same concentrations cocaine had no measurable effect on increases in platelet cytosolic calcium, a primary event associated with platelet activation. Platelet cytoskeletal preparations. Triton X-100-insoluble cytoskeletons of cocaine-and carrier-treated platelets in plasma were prepared according to the previously published methods.2425 Cytoskeletal proteins were identified by their electrophoretic properties through sodium dodecyl sulfate (SDS)-polyacrylamide gels compared with protein standards and by their solubility properties in Triton X-100-containing buffers.24 Platelets were either pretreated with 0.1% cocaine for aggregation studies or treated with 0.2% cocaine for disaggregation studies as described in the "Methods" section entitled "Platelet aggregation." PRP was removed directly from the aggregometer cuvette and immediately lysed with 0.5 mL of ice-cold 2% Triton X-100 extraction buffer containing 100 mmol/L tris(hydroxymethyl)aminomethane (Tris) HCl, 10 mmol/L ethylene glycol-bis(,1-aminoethyl ether) N,NN',N' tetraacetic acid, 2 mmol/L 2-mercaptoethanol, and 2 ,mol/L leupeptin, pH 7.4 (2x extraction buffer). The sample was vortexed for 10 seconds and centrifuged at 10 OOOg for 5 minutes. The supernatant was discarded and the pellet washed two times in 1 x extraction buffer. Reducing sample buffer (0.5 mL) consisting of 2% SDS, 2% 2-mercaptoethanol, 10% glycerol, 0.01% bromophenol blue, and 50 mmol/L Tris HCl, pH 6.8, was added to the final pellet. The sample was then heated for 10 minutes at 100°C. Solubilized whole platelet proteins were prepared by adding two drops of Sequester-Sol to citrated PRP and then centrifuging at 1600g for 10 minutes. The supernatant was removed, and the pellet was washed once in buffer containing 140 mmol/L NaCl, 20 mmol/L N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), and 1 mmol/L ethylenediaminetetraacetic acid, pH 7.1, and resuspended in buffer containing 137 mmol/L NaCl, 2.7 mmol/L KCl, 1 mmol/L MgCl2, 3 .3 mmol/L NaH2PO4, and 20 mmol/L HEPES, pH 7.4, to half the original volume. An equal volume of sample buffer was then added for SDS-polyacrylamide gel electrophoresis analysis.
Materials and Methods
Gel electrophoresis. Samples were electrophoresed through 5% to 20% SDS-polyacrylamide exponential gradient gels overnight at a constant voltage of 25 V.26 Proteins were visualized by staining with Coomassie brilliant blue.
Immunoblotting. An LKB 2005 Transfer Electroblotter was used to transfer polypeptides from SDS-polyacrylamide gels to nitrocellulose sheets. The transfer buffer contained 25 mmol/L Tris, 10 mmol/L glycine, and 20% methanol, pH 8.3. Proteins were electrotransferred for 1 hour at 0.7 mA.27 After transfer, the nitrocellulose sheets were incubated overnight with 10 mmol/L Tris, 0.9% NaCl, and 3% bovine serum albumin (BSA), pH 7.4 (immune stain buffer). Primary antibody (1:500) was added to the immune stain buffer, and nitrocellulose sheets were incubated for 16 hours. The membrane was washed four times with 10 mmol/L Tris, 0.9% NaCl, and 1% BSA, pH 7.4 (immune incubation buffer). Visualization of bound antibody was achieved by incubating the membrane with species-specific anti- 
Results
To evaluate the effect of cocaine on platelet aggregation, platelets from four medication-free donors were preincubated with increasing concentrations of cocaine or carrier and challenged with the agonists ADP (10 ,umol/L) or collagen (2 ,ug/mL) in the aggregometer (Fig 1) . We found that the aggregation response to both agonists was inhibited by cocaine in a concentrationdependent manner. The addition of carrier had no effect on the aggregation response to either ADP or collagen (data not shown). When ADP was the agonist, the platelet aggregation responses were inhibited completely by 0.2% cocaine (Fig 1A) . With respect to collagen, the aggregation responses were completely inhibited by 0.1% cocaine (Fig iB) . This inhibition of aggregation appeared to be specifically related to the ability of platelets to bind fibrinogen because shape change in response to ADP addition was observed (data not shown). Behnke7 previously showed that platelets treated with cocaine at a concentration of 3000 ,ug/mL (0.3%) inhibited shape change in response to 1 ,ug/mL ADP. Thus, it is possible that higher concentrations of anesthetics are required to inhibit this response. Previous reports have suggested that low-dose cocaine (0.005% to 0.05%) enhances the response of rabbit platelets to nonaggregating levels of arachidonic acid, thus leading to increased platelet reactivity rather than inhibition.20 When we pretreated platelets with 0.2% cocaine, the aggregation response to 500 ,lg/mL arachidonic acid was totally inhibited (Table 1 ). In addition, cocaine was able to induce disaggregation of preformed platelet aggregates (data not shown). Since we observed inhibitory effects of cocaine similar to those seen when platelets were stimulated with ADP and collagen, we investigated the reported enhanced platelet response to subthreshold levels of arachidonic acid in the presence of cocaine (Table 1) . First, we established our subthreshold level of arachidonic acid.
When platelets were challenged with 100 ,ug/mL arachidonic acid, they did not aggregate; however, treatment with greater than 100 ,ug/mL elicited a measurable aggregation response. Based on these experiments 100 ,ug/mL was selected as our subthreshold concentration.
In the process of setting up our assay system we found that, in contrast to all our other aggregation assays in which carrier controls caused no effect on aggregation, the addition of the carrier (0.2%) to platelets caused a marked aggregation response (82% to 89%, n=3) to subthreshold amounts of arachidonic acid. However, when the platelets were treated with 0.02% carrier diluted in saline, the platelets had an aggregation response of 5% or less when challenged with 100 jug/mL arachidonic acid. As expected, platelets preincubated with 10-fold less cocaine (0.02%) diluted in saline rather than carrier did not aggregate in response to subthreshold amounts of arachidonic acid; however, platelets incubated with 0.02% cocaine diluted in carrier rather than saline showed a 75% to 93% aggregation response to 100 ,ug/mL of arachidonic acid. As the concentration of cocaine in the carrier was increased (greater than or equal to 0.04%), the aggregatory effect of the carrier was abolished. Thus, cocaine does inhibit arachidonic acid-mediated platelet aggregation, and it appears that carrier and not cocaine is responsible for an enhanced response of human platelets to subthreshold levels of this agonist. Based on our studies it is difficult to support the hypothesis that cocaine causes an enhanced aggregatory response of human platelets to agonists in vivo. We would suggest that cocaine may inhibit platelet function particularly when high local concentrations are achieved.
To determine whether cocaine had the capacity to disaggregate platelets and possibly affect preformed aggregates in the circulation in vivo, cocaine was added at increasing concentrations 3 minutes after the initiation of aggregation induced by ADP or collagen (Fig 2A  and 2B ). We found that disaggregation due to the presence of cocaine was dependent on the concentration of drug added. Maximal disaggregation was seen at approximately 0.4% cocaine with both agonists. Con The results from the above experiments suggest that cocaine dramatically affects fibrinogen binding to activated platelets. The following experiments were designed to determine whether cocaine specifically altered ligand binding to GPIIb-IIIa, the human platelet fibrinogen receptor, or if cocaine at the same concentration inhibited other calcium-dependent pathways that would normally lead to platelet activation, fibrinogen binding, and platelet aggregation. It has been suggested that cocaine, along with other local anesthetics such as dibucaine, tetracaine, and lidodaine, may perturb cell membrane phospholipid organization by displacing calcium from the membrane and modifying cellular calcium homeostasis.9
Since platelet cytoplasmic free calcium plays a central role in platelet activation, we examined whether cocaine altered agonist-induced increases in platelet cytosolic calcium. Indo-1-loaded platelets were preincubated with 0.2% cocaine and then challenged with either ADP or thrombin (Table 3) . Response was compared with that obtained when platelets were preincubated with the drug vehicle. We found that the addition of cocaine did not inhibit increases in cytosolic free calcium levels normally observed when platelets are challenged with ADP or thrombin. Thus, it appears that cocaine at the concentrations used in this study does not have a general effect on platelet reactivity by altering all physiological responses dependent on the availability of calcium ions but does specifically alter fibrinogen binding, thereby preventing platelet aggregation.
Following platelet activation, alterations in the platelet cytoskeleton include a net polymerization of monomeric actin into filaments and an increased association of these filaments with other cytoskeletal proteins. 24, 29, 30 Platelet secretion, shape change, aggregation, and clot retraction require the forces generated by the interaction of these contractile proteins. Further examination of the mechanism by which cocaine affects platelet reactivity was carried out by examining the organization of the cytoskeletal core of platelets pretreated with cocaine or the carrier control. In addition, the composition of the cytoskeleton when cocaine-treated platelets were challenged with the agonists ADP or collagen was analyzed. Cytoskeletal cores of platelets in plasma were isolated by solubilization with Triton X-100 extraction buffer and centrifugation at 10 000g. The cores were analyzed for protein content by SDS-polyacrylamide gel electrophoresis. Fig 3 is (lanes 5 and 6) but was similar to the levels observed when treated with carrier or cocaine in the absence of agonist. As anticipated, treatment with carrier before agonist addition had no effect on the composition of the cores (lanes 7 and 8) .
When platelet aggregates were dissociated by cocaine addition (lanes 9 and 10), the retention of ABP, talin, a-actinin, myosin, and actin in the cytoskeletal cores was reduced when compared with those residues isolated from aggregated platelets in the presence (lanes 11 and 12) or absence (lanes 1 and 2) of carrier. Therefore, our results suggest that cocaine not only affected organization of the contractile cytoskeletal assembly composed of primarily actin and myosin but also disrupted the platelet pseudopodial cytoskeleton previously suggested to be composed primarily of ABP and a-actinin. 29 The levels of cytoskeletal elements remaining in the isolated cores reflected the extent of disaggregation achieved by cocaine treatment.
One possible explanation for alterations in cytoskeletal organization is cocaine-induced activation of the calcium-dependent protease that hydrolyzes ABP and talin, primary components of the cytoskeletal network. Previous studies by Nachmias et al '3 showed that lowsalt precipitates isolated from human platelets pretreated with 2 mmol/L tetracaine had major reductions of bands 1 and 2 (presumably ABP and talin) and increases in the staining intensity of some bands in the lower-molecular-weight regions. Our studies show that the decreased ABP incorporation in the residues from cocaine-treated platelets was not due to its proteolysis by platelet calcium-dependent proteases in the intact platelet because (1) cocaine does not stimulate calcium influx and (2) ABP and talin in intact platelets were not degraded by these proteases during a 5-minute incubation period with cocaine (Fig 4) . It is possible that increased susceptibility of ABP and talin to proteolysis occurred once the platelets were lysed by Triton X-100.
Interestingly, as reported earlier with lidocainetreated platelets,13 we did find subtle differences in the protein content of solubilized platelets depending on whether they were exposed to cocaine or carrier. These alterations may in part explain the inhibitory effect of cocaine on platelet function. Fig 4 shows the Coomassie blue-stained gels of SDS-solubilized whole platelet proteins that were electrophoresed through a gradient polyacrylamide gel. At concentrations of 0.02% (lanes 1 and 2), the protein staining pattern of either the cocaine-or carrier-treated platelets appeared identical and was indistinguishable from that of PBS-treated platelets (data not shown). However, when 0.2% cocaine was incubated with the platelets (lane 3), the staining pattern of three regions was affected in the apparent molecular weight ranges of 170 to 180 kD, 75 kD, and 27 kD. The identification of these altered proteins has not been carried out, but it is possible that their alteration may in part contribute to the profound effects that cocaine and possibly other anesthetics have on platelet function. The appearance of the new 27-kD protein in the cocaine-treated samples may represent a degradation product(s) of one or more higher-molecular-weight proteins.
Studies by Phillips et a130 showed that after thrombinstimulated platelet aggregation, a subpopulation of GPIIb-IlIa became associated with the Triton X-100-insoluble cytoskeleton. Further studies suggested that GPIIb-IIla association with the cytoskeleton was dependent on both the degree of aggregation and the formation of the pseudopodial cytoskeletal assembly.29 Because both of these processes are affected by cocaine treatment, we examined the effect of cocaine exposure on GPILb-IIIa incorporation into the Triton X-100 residue.
Immunoblotting was used to demonstrate that GPIIb-IIla was incorporated into the Triton X-100-insoluble cytoskeletons of ADP-and collagen-aggregated platelets (Fig 5, lanes 1 and 2) . In contrast, GPIIb-IIIa was not detected in the insoluble cytoskeletons of platelets that had been preincubated with cocaine (0.2%) before agonist addition (lanes 3 and 4) Discussion The deleterious effects of cocaine on the cerebrovascular system have been well documented. Much less is understood about the direct effect of cocaine on human platelet function and the possible contribution of this effect to cocaine-mediated stroke. To elucidate further the potential effects of cocaine on hemostasis, we examined the effect of cocaine on human platelet aggregation and platelet activation responses such as platelet cytosolic free calcium levels, the organization of the platelet cytoskeleton, and fibrinogen binding. Our data support the following conclusions: (1) cocaine prevents the binding of fibrinogen to agonist-stimulated platelets and can bring about the dissociation of fibrinogen bound to platelets incorporated into a platelet aggregate, thus causing platelet disaggregation; (2) cocaine does not inhibit agonist-mediated increases in platelet cytosolic calcium, and therefore a central mechanism that governs the reactivity of the human platelet is still intact; and (3) cocaine affects the organization of the platelet cytoskeleton and inhibits the increased association of ABP, myosin, a-actinin, and actin as well as GPILIb-llla in the Triton X-100-insoluble residue of ADP-or collagen-aggregated platelets. Our in vitro data suggest that cocaine has a dramatic effect on mechanisms responsible for mediating both adhesive and cohesive properties of platelets.
It has been difficult to determine the systemic levels of cocaine in patients admitted to the hospital for cocaine abuse due to its short half-life (0.8 to 1.25 hours).31 The fatal dose of cocaine has been approximated to be 1.2 g, although severe toxic effects have been reported from doses as low as 20 ng.32,33 Thus, based on blood volumes of an average-sized person (5 L), the concentrations of cocaine that caused platelet inhibition in our in vitro experiments are within an order of magnitude of the predicted systemic concentration of lethal doses of cocaine. An earlier attempt was made to examine an ex vivo effect of cocaine on platelet function by studying platelets from patients with documented cocaine abuse and cerebral hemorrhage. While depressed platelet function was observed, interpretation of the direct effects of cocaine abuse on platelet function was not possible since each individual had also ingested other drugs (eg, aspirin, alcohol) known to depress platelet function. Whether depressed platelet function due to cocaine abuse or due to a combination of drugs is clinically relevant to the incidence of cerebral hemorrhage or to the management of these patients remains to be determined.
